Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECX vs CX in Advanced Gastric Cancer
NCT00743964Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Apr 2008
- Primary completion
- Oct 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epirubicin in gastric cancer (GC) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Failure-free survival at 6 months. Started Apr 2008; status: completed.
02
Drugs
epirubicin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00743964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00743964.